StockData
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics (MLTX) stock

MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$10.79−0.46 (-4.09%)

Close on Nov 18, 2026Market cap $918.30MP/E –Yield –

MoonLake Immunotherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

MoonLake Immunotherapeutics's operating income for the twelve months ending Jun 30, 2026 was -$268.34M. For fiscal 2025 it was -$244.83M. The highest annual figure on record is -$4.57M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$244.83M–
FY2024Dec 31, 2024-$143.09M–
FY2023Dec 31, 2023-$54.12M–
FY2022Dec 31, 2022-$65.06M–
FY2021Dec 31, 2021-$4.57M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$61.66M–
Q1 FY2026Mar 31, 2026-$70.02M–
Q4 FY2025Dec 31, 2025-$65.22M–
Q3 FY2025Sep 30, 2025-$71.43M–
Q2 FY2025Jun 30, 2025-$60.70M–
Q1 FY2025Mar 31, 2025-$47.49M–
Q4 FY2024Dec 31, 2024-$49.58M–
Q3 FY2024Sep 30, 2024-$43.11M–
Q2 FY2024Jun 30, 2024-$30.58M–
Q1 FY2024Mar 31, 2024-$19.82M–
Q4 FY2023Dec 31, 2023-$15.03M–
Q3 FY2023Sep 30, 2023-$12.98M–
Q2 FY2023Jun 30, 2023-$13.19M–
Q1 FY2023Mar 31, 2023-$12.93M–
Q4 FY2022Dec 31, 2022-$16.70M-148.1%
Q3 FY2022Sep 30, 2022-$14.77M–
Q2 FY2022Jun 30, 2022-$17.65M–
Q1 FY2022Mar 31, 2022-$15.94M–
Q4 FY2021Dec 31, 2021$34.73M–
Q3 FY2021Sep 30, 2021-$6.27M–
Q2 FY2021Jun 30, 2021-$32.68M–
Q1 FY2021Mar 31, 2021-$94.11K–

More MoonLake Immunotherapeutics figures

See a number that looks wrong?